Enhancing the efficacy of drug-loaded nanocarriers against brain tumors by targeted radiation therapy

Oncotarget

Volumn 4, Issue 1, 2013, Pages 64-79

  Baumann, Brian C ^a   Kao, Gary D ^a   Mahmud, Abdullah ^b   Harada, Takamasa ^b   Swift, Joe ^b   Chapman, Christina ^a   Xu, Xiangsheng ^a   Discher, Dennis E ^b   Dorsey, Jay F ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Brain tumors; Chemotherapy; Glioblastoma multiforme; Nanocarrier; Radiation therapy

Indexed keywords

NANOCARRIER; PACLITAXEL; POLY(EPSILON CAPROLACTONE RANDOM DEXTRO,LEVO LACTIDE); POLYMER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; BRAIN RADIATION; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SURVIVAL; CHEMORADIOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; OVERALL SURVIVAL; SURVIVAL TIME;

EID: 84875767677     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.777     Document Type: Article

References (53)

1. American Cancer Society I. (2010). Cancer Facts & Figures. (Atlanta, GA: American Cancer Society).
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352(10):987-996.
3. Gao Y, Fotovati A, Lee C, Wang M, Cote G, Guns E, Toyota B, Faury D, Jabado N and Dunn SE. Inhibition of Y-box binding protein-1 slows the growth of glioblastoma multiforme and sensitizes to temozolomide independent O6-methylguanine-DNA methyltransferase. Molecular cancer therapeutics. 2009; 8(12):3276-3284.
4. Langer CJ, Ruffer J, Rhodes H, Paulus R, Murray K, Movsas B and Curran W. Phase II radiation therapy oncology group trial of weekly paclitaxel and conventional external beam radiation therapy for supratentorial glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2001; 51(1):113-119.
5. Iyer AK, Khaled G, Fang J and Maeda H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today. 2006; 11(17-18):812-818.
6. Luo Y and Prestwich GD. Cancer-targeted polymeric drugs. Curr Cancer Drug Targets. 2002; 2(3):209-226.
7. Muldoon LL, Soussain C, Jahnke K, Johanson C, Siegal T, Smith QR, Hall WA, Hynynen K, Senter PD, Peereboom DM and Neuwelt EA. Chemotherapy delivery issues in central nervous system malignancy: a reality check. J Clin Oncol. 2007; 25(16):2295-2305.
8. Ewing JR, Brown SL, Lu M, Panda S, Ding G, Knight RA, Cao Y, Jiang Q, Nagaraja TN, Churchman JL and Fenstermacher JD. Model selection in magnetic resonance imaging measurements of vascular permeability: Gadomer in a 9L model of rat cerebral tumor. J Cereb Blood Flow Metab. 2006; 26(3):310-320.
9. Mann AP, Bhavane RC, Somasunderam A, Liz Montalvo-Ortiz B, Ghaghada KB, Volk D, Nieves-Alicea R, Suh KS, Ferrari M, Annapragada A, Gorenstein DG and Tanaka T. Thioaptamer conjugated liposomes for tumor vasculature targeting. Oncotarget. 2011; 2(4):298-304.
10. Qiao Y, Huang X, Nimmagadda S, Bai R, Staedtke V, Foss CA, Cheong I, Holdhoff M, Kato Y, Pomper MG, Riggins GJ, Kinzler KW, Diaz LA, Jr., Vogelstein B and Zhou S. A robust approach to enhance tumor-selective accumulation of nanoparticles. Oncotarget. 2011; 2(1-2):59-68.
11. Christian DA, Cai S, Garbuzenko OB, Harada T, Zajac AL, Minko T and Discher DE. Flexible filaments for in vivo imaging and delivery: persistent circulation of filomicelles opens the dosage window for sustained tumor shrinkage. Mol Pharm. 2009; 6(5):1343-1352.
12. Loverde SM, Klein ML and Discher DE. Nanoparticle shape improves delivery: rational coarse grain molecular dynamics (rCG-MD) of taxol in worm-like PEG-PCL micelles. Advanced materials. 2012; 24(28):3823-3830.
13. Discher DE, Ortiz V, Srinivas G, Klein ML, Kim Y, Christian D, Cai S, Photos P and Ahmed F. Emerging applications of polymersomes in delivery: From molecular dynamics to shrinkage of tumors. Prog Polym Sci. 2007; 32(8-9):838-857.
14. Jahnke K, Doolittle ND, Muldoon LL and Neuwelt EA. Implications of the blood-brain barrier in primary central nervous system lymphoma. Neurosurg Focus. 2006; 21(5):E11.
15. Guillaume DJ, Doolittle ND, Gahramanov S, Hedrick NA, Delashaw JB and Neuwelt EA. Intra-arterial chemotherapy with osmotic blood-brain barrier disruption for aggressive oligodendroglial tumors: results of a phase I study. Neurosurgery. 2010; 66(1):48-58; discussion 58.
16. Neuwelt E, Abbott NJ, Abrey L, Banks WA, Blakley B, Davis T, Engelhardt B, Grammas P, Nedergaard M, Nutt J, Pardridge W, Rosenberg GA, Smith Q and Drewes LR. Strategies to advance translational research into brain barriers. Lancet Neurol. 2008; 7(1):84-96.
17. Doolittle ND, Miner ME, Hall WA, Siegal T, Jerome E, Osztie E, McAllister LD, Bubalo JS, Kraemer DF, Fortin D, Nixon R, Muldoon LL and Neuwelt EA. Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors. Cancer. 2000; 88(3):637-647.
18. Deeken JF and Loscher W. The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin Cancer Res. 2007; 13(6):1663-1674.
19. Saito R, Bringas JR, McKnight TR, Wendland MF, Mamot C, Drummond DC, Kirpotin DB, Park JW, Berger MS and Bankiewicz KS. Distribution of liposomes into brain and rat brain tumor models by convection-enhanced delivery monitored with magnetic resonance imaging. Cancer research. 2004; 64(7):2572-2579.
20. Hynynen K, McDannold N, Vykhodtseva N and Jolesz FA. Noninvasive MR imaging-guided focal opening of the blood-brain barrier in rabbits. Radiology. 2001; 220(3):640-646.
21. Cao Y, Tsien CI, Shen Z, Tatro DS, Ten Haken R, Kessler ML, Chenevert TL and Lawrence TS. Use of magnetic resonance imaging to assess blood-brain/blood-glioma barrier opening during conformal radiotherapy. J Clin Oncol. 2005; 23(18):4127-4136.
22. Lemasson B, Serduc R, Maisin C, Bouchet A, Coquery N, Robert P, Le Duc G, Tropres I, Remy C and Barbier EL. Monitoring blood-brain barrier status in a rat model of glioma receiving therapy: dual injection of low-molecularweight and macromolecular MR contrast media. Radiology. 2010; 257(2):342-352.
23. Patel RR and Mehta MP. Targeted therapy for brain metastases: improving the therapeutic ratio. Clin Cancer Res. 2007; 13(6):1675-1683.
24. Li YQ, Chen P, Haimovitz-Friedman A, Reilly RM and Wong CS. Endothelial apoptosis initiates acute blood-brain barrier disruption after ionizing radiation. Cancer research. 2003; 63(18):5950-5956.
25. Yuan H, Gaber MW, Boyd K, Wilson CM, Kiani MF and Merchant TE. Effects of fractionated radiation on the brain vasculature in a murine model: blood-brain barrier permeability, astrocyte proliferation, and ultrastructural changes. Int J Radiat Oncol Biol Phys. 2006; 66(3):860-866.
26. van Vulpen M, Kal HB, Taphoorn MJ and El-Sharouni SY. Changes in blood-brain barrier permeability induced by radiotherapy: implications for timing of chemotherapy? (Review). Oncology reports. 2002; 9(4):683-688.
27. Diserbo M, Agin A, Lamproglou I, Mauris J, Staali F, Multon E and Amourette C. Blood-brain barrier permeability after gamma whole-body irradiation: an in vivo microdialysis study. Canadian journal of physiology and pharmacology. 2002; 80(7):670-678.
28. Qin DX, Zheng R, Tang J, Li JX and Hu YH. Influence of radiation on the blood-brain barrier and optimum time of chemotherapy. Int J Radiat Oncol Biol Phys. 1990; 19(6):1507-1510.
29. Geng Y, Dalhaimer P, Cai S, Tsai R, Tewari M, Minko T and Discher DE. Shape effects of filaments versus spherical particles in flow and drug delivery. Nat Nanotechnol. 2007; 2(4):249-255.
30. El-Deiry WS, Sigman CC and Kelloff GJ. Imaging and oncologic drug development. J Clin Oncol. 2006; 24(20):3261-3273.
31. Rice A, Michaelis ML, Georg G, Liu Y, Turunen B and Audus KL. Overcoming the blood-brain barrier to taxane delivery for neurodegenerative diseases and brain tumors. J Mol Neurosci. 2003; 20(3):339-343.
32. Xin H, Chen L, Gu J, Ren X, Wei Z, Luo J, Chen Y, Jiang X, Sha X and Fang X. Enhanced anti-glioblastoma efficacy by PTX-loaded PEGylated poly(varepsilon-caprolactone) nanoparticles: In vitro and in vivo evaluation. Int J Pharm. 2010; 402(1-2):238-247.
33. Candolfi M, Curtin JF, Nichols WS, Muhammad AG, King GD, Pluhar GE, McNiel EA, Ohlfest JR, Freese AB, Moore PF, Lerner J, Lowenstein PR and Castro MG. Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression. J Neurooncol. 2007; 85(2):133-148.
34. Baumann BC, Benci JL, Santoiemma PP, Chandrasekaran S, Hollander AB, Kao GD and Dorsey JF. An integrated method for reproducible and accurate image-guided stereotactic cranial irradiation of brain tumors using the small animal radiation research platform. Translational oncology. 2012; 5(4):230-237.
35. Radaelli E, Ceruti R, Patton V, Russo M, Degrassi A, Croci V, Caprera F, Stortini G, Scanziani E, Pesenti E and Alzani R. Immunohistopathological and neuroimaging characterization of murine orthotopic xenograft models of glioblastoma multiforme recapitulating the most salient features of human disease. Histol Histopathol. 2009; 24(7):879-891.
36. Liu B, Wang L, Shen LL, Shen MZ, Guo XD, Wang T, Liang QC, Wang C, Zheng J, Li Y, Jia LT, Zhang H and Gao GD. RNAi-mediated inhibition of presenilin 2 inhibits glioma cell growth and invasion and is involved in the regulation of Nrg1/ErbB signaling. Neuro-oncology. 2012; 14(8):994-1006.
37. Yan W, Qian C, Zhao P, Zhang J, Shi L, Qian J, Liu N, Fu Z, Kang C, Pu P and You Y. Expression pattern of osteopontin splice variants and its functions on cell apoptosis and invasion in glioma cells. Neuro-oncology. 2010; 12(8):765-775.
38. Dennis E. Discher, Vanessa Ortiz, Goundla Srinivas, Michael L. Klein, Younghoon Kim, David Christian, Shenshen Cai, Peter Photos, Fariyal Ahme. Emerging applications of polymersomes in delivery: From molecular dynamics to shrinkage of tumors. Progress in Polymer Science. 2007; 32:838-857.
39. Ay I, Francis JW and Brown RH. VEGF increases bloodbrain barrier permeability to Evans blue dye and tetanus toxin fragment C but not adeno-associated virus in ALS mice. Brain Res. 2008; 1234:198-205.
40. Kozler P and Pokorny J. Altered blood-brain barrier permeability and its effect on the distribution of Evans blue and sodium fluorescein in the rat brain applied by intracarotid injection. Physiol Res. 2003; 52(5):607-614.
41. Discher DE, Rajagopal K, Mahmud A, Christian DA, Pajerowski JD, Brown AEX and Loverde SM. Curvature-Coupled Hydration of Semicrystalline Polymer Amphiphiles Yields flexible Worm Micelles but Favors Rigid Vesicles: Polycaprolactone-Based Block Copolymers. Macromolecules. 2010; 43(23):9736-9746.
42. Baumann BC, Dorsey JF, Benci JL, Joh DY and Kao GD. Stereotactic Intracranial Implantation and In vivo Bioluminescent Imaging of Tumor Xenografts in a Mouse Model System of Glioblastoma Multiforme. J Vis Exp. 2012; (67).
43. Zhang X, Burt HM, Von Hoff D, Dexter D, Mangold G, Degen D, Oktaba AM and Hunter WL. An investigation of the antitumour activity and biodistribution of polymeric micellar paclitaxel. Cancer Chemother Pharmacol. 1997; 40(1):81-86.
44. Lee KH, Byun SS, Paik JY, Lee SY, Song SH, Choe YS and Kim BT. Cell uptake and tissue distribution of radioiodine labelled D-luciferin: implications for luciferase based gene imaging. Nucl Med Commun. 2003; 24(9):1003-1009.
45. Hawes JJ and Reilly KM. Bioluminescent approaches for measuring tumor growth in a mouse model of neurofibromatosis. Toxicol Pathol. 2010; 38(1):123-130.
46. Prasad G, Sottero T, Yang X, Mueller S, James CD, Weiss WA, Polley MY, Ozawa T, Berger MS, Aftab DT, Prados MD and Haas-Kogan DA. Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide. Neuro Oncol. 2011; 13(4):384-392.
47. Weissleder R and Pittet MJ. Imaging in the era of molecular oncology. Nature. 2008; 452(7187):580-589.
48. Shin JW, Swift J, Spinler KR and Discher DE. Myosin-II inhibition and soft 2D matrix maximize multinucleation and cellular projections typical of platelet-producing megakaryocytes. Proc Natl Acad Sci U S A. 2011; 108(28):11458-11463.
49. Wong J, Armour E, Kazanzides P, Iordachita I, Tryggestad E, Deng H, Matinfar M, Kennedy C, Liu Z, Chan T, Gray O, Verhaegen F, McNutt T, Ford E and DeWeese TL. Highresolution, small animal radiation research platform with x-ray tomographic guidance capabilities. Int J Radiat Oncol Biol Phys. 2008; 71(5):1591-1599.
50. Triscott J, Lee C, Hu K, Fotovati A, Berns R, Pambid M, Luk M, Kast RE, Kong E, Toyota E, Yip S, Toyota B and Dunn SE. Disulfiram, a drug widely used to control alcoholism, suppresses the self-renewal of glioblastoma and over-rides resistance to temozolomide. Oncotarget. 2012; 3(10):1112-1123.
51. Hothi P, Martins TJ, Chen L, Deleyrolle L, Yoon JG, Reynolds B and Foltz G. High-throughput chemical screens identify disulfiram as an inhibitor of human glioblastoma stem cells. Oncotarget. 2012; 3(10):1124-1136.
52. Lockman PR, Mittapalli RK, Taskar KS, Rudraraju V, Gril B, Bohn KA, Adkins CE, Roberts A, Thorsheim HR, Gaasch JA, Huang S, Palmieri D, Steeg PS and Smith QR. Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin Cancer Res. 2010; 16(23):5664-5678.
53. Vinchon-Petit S, Jarnet D, Paillard A, Benoit JP, Garcion E and Menei P. In vivo evaluation of intracellular drug-nanocarriers infused into intracranial tumours by convection-enhanced delivery: distribution and radiosensitisation efficacy. J Neurooncol. 2010; 97(2):195-205